For the Inventor, By the Inventor

Enter assignee name

Hwaseong-si, South Korea

Hanmi Science Co., Ltd.

USPTO Granted Patents = 63

CIPO Patents = 12

EPO Patents = 63

Trademarks = 5

Forward Citations = 178

Loading Chart...

Loading Chart...

144 inventors (with patents filed for the assignee):

Se Chang Kwon (41 out of 89 patents)

Sung Youb Jung (23 out of 62 patents)

Gwan Sun Lee (21 out of 44 patents)

4. Sung Min Bae (11 out of 30 patents)

5. Young Jin Park (10 out of 88 patents)

6. Dae Hae Song (10 out of 15 patents)

7. Dae Jin Kim (10 out of 33 patents)

8. Maeng Sup Kim (9 out of 14 patents)

9. Myung Hyun Jang (8 out of 15 patents)

10. In Young Choi (8 out of 31 patents)

11. Sung H Hong (8 out of 100 patents)

12. Dae Seong Im (6 out of 6 patents)

13. Jin Sun Kim (6 out of 10 patents)

14. Young Kyung Park (6 out of 6 patents)

15. Jae Hee Shin (6 out of 6 patents)

Core Competencies:

Oxyntomodulin Derivatives

Immunoglobulin Fragment

Polypeptide Complex

Insulin Conjugate

Long-Acting Formulation

Protein Kinase Inhibitors

Cancer Treatment

Diabetes Composition

Blood Coagulation Factor

Recombinant Protein Production

Pharmaceutical Composition

Drug Carrier

63 patents: Sort by Forward Citations

1. 11872283 - Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof (2024-01-16),

2. 11434271 - Method for preparing physiologically active polypeptide complex (2022-09-06),

3. 11168109 - Process for preparation of physiologically active polypeptide complex (2021-11-09),

4. 11058776 - IgG Fc fragment for a drug carrier and method for the preparation thereof (2021-07-13),

5. 11040110 - Polypeptide complex comprising non-peptidyl polymer having three functional ends (2021-06-22),

6. 10744187 - Insulin conjugate using an immunoglobulin fragment (2020-08-18),

7. 10442848 - Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same (2019-10-15),

8. 10363320 - Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof (2019-07-30),

9. 10272159 - IgG Fc fragment for a drug carrier and method for the preparation thereof (2019-04-30),

10. 10251957 - Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate (2019-04-09),

11. 10112954 - Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase (2018-10-30),

12. 10071171 - Polypeptide complex comprising non-peptidyl polymer having three functional ends (2018-09-11),

13. 10071166 - Protein complex using an immunoglobulin fragment and method for the preparation thereof (2018-09-11),

14. 10064951 - Liquid formulation of highly concentrated long-acting human growth hormone conjugate (2018-09-04),

15. 9981017 - Insulin conjugate using an immunoglobulin fragment (2018-05-29),

Hanmi Science Co., Ltd. is a company based in South Korea. It specializes in providing comprehensive solutions in the field of information technology (IT) and consulting services. With their expertise and experience, Hanmi Science assists organizations in managing and optimizing their IT infrastructure, implementing effective security measures, and leveraging technology to achieve business goals. They offer a wide range of services including IT system development, network infrastructure design, cloud computing solutions, data analytics, and IT consulting. Hanmi Science aims to support their clients in achieving digital transformation and enhancing operational efficiency through innovative IT solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

63 Patents

#5 in Hwaseong-si

#264 in South Korea

#11,330 in the World

Hwaseong-si, South Korea

Hanmi Science Co., Ltd.

Forward Citations = 178

144 inventors:

Se Chang Kwon (41 out of 89 patents)

Sung Youb Jung (23 out of 62 patents)

Gwan Sun Lee (21 out of 44 patents)

4. Sung Min Bae (11 out of 30 patents)

5. Young Jin Park (10 out of 88 patents)

Please report any incorrect information to support@idiyas.com

Loading…